Oncogenic mutations in RAS genes, like KRASG12D or NRASG12D, trap Ras in the active state and cause myeloproliferative disorder and T cell leukemia (T-ALL) when induced in the bone marrow via Mx1CRE. The RAS exchange factor RASGRP1 is frequently overexpressed in T-ALL patients. In T-ALL cell lines overexpression of RASGRP1 increases flux through the RASGTP/RasGDP cycle. Here we expanded RASGRP1 expression surveys in pediatric T-ALL and generated a RoLoRiG mouse model crossed to Mx1CRE to determine the consequences of induced RASGRP1 overexpression in primary hematopoietic cells. RASGRP1-overexpressing, GFP-positive cells outcompeted wild type cells and dominated the peripheral blood compartment over time. RASGRP1 overexpression bestows gain-of-function colony formation properties to bone marrow progenitors in medium containing limited growth factors. RASGRP1 overexpression enhances baseline mTOR-S6 signaling in the bone marrow, but not in vitro cytokine-induced signals. In agreement with these mechanistic findings, hRASGRP1-ires-EGFP enhances fitness of stem- and progenitor- cells, but only in the context of native hematopoiesis. RASGRP1 overexpression is distinct from KRASG12D or NRASG12D, does not cause acute leukemia on its own, and leukemia virus insertion frequencies predict that RASGRP1 overexpression can effectively cooperate with lesions in many other genes to cause acute T-ALL.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577. https://doi.org/10.1038/bcj.2017.53.
von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR. Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Cancer Res. 2000;6:1804–10.
Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, et al. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci Signal. 2013;6:ra21. https://doi.org/10.1126/scisignal.2003848.
Ksionda O, Melton AA, Bache J, Tenhagen M, Bakker J, Harvey R, et al. RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines. Oncogene. 2016;35:3658–68. https://doi.org/10.1038/onc.2015.431.
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8. https://doi.org/10.1101/gad.943001.
Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308. https://doi.org/10.1038/nrc2109.
Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113–9. https://doi.org/10.1182/blood-2005-03-0867.
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8. https://doi.org/10.1038/ng.3909.
Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427–9.
Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528–38. https://doi.org/10.1172/JCI20476.
Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:597–602.
Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood. 2008;112:3373–82.
Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009;7:e59.
Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood. 2010;116:5991–6002. https://doi.org/10.1182/blood-2010-04-281527.
Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011;117:2022–32. https://doi.org/10.1182/blood-2010-04-280750.
Oki-Idouchi CE, Lorenzo PS. Transgenic overexpression of RasGRP1 in mouse epidermis results in spontaneous tumors of the skin. Cancer Res. 2007;67:276–80.
Klinger MB, Guilbault B, Goulding RE, Kay RJ. Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors. Oncogene. 2005;24:2695–704.
Oki T, Kitaura J, Watanabe-Okochi N, Nishimura K, Maehara A, Uchida T, et al. Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis. Leukemia. 2012;26:1038–45. https://doi.org/10.1038/leu.2011.328.
Norment AM, Bogatzki LY, Klinger M, Ojala EW, Bevan MJ, Kay RJ. Transgenic expression of RasGRP1 induces the maturation of double-negative thymocytes and enhances the production of CD8 single-positive thymocytes. J Immunol. 2003;170:1141–9.
Jun JE, Rubio I, Roose JP. Regulation of Ras exchange factors and cellular localization of Ras activation by lipid messengers in T cells. Front Immunol. 2013;4:239. https://doi.org/10.3389/fimmu.2013.00239.
Ksionda O, Limnander A, Roose JP. RasGRP Ras guanine nucleotide exchange factors in cancer. Front Biol (Beijing). 2013;8:508–32. https://doi.org/10.1007/s11515-013-1276-9.
Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with t-lineage acute lymphoblastic leukemia: results from the children’s oncology group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36:2926–34. https://doi.org/10.1200/JCO.2018.77.7250.
Ksionda, O, Melton, AA, Bache, J, Tenhagen, M, Bakker, J, Harvey, R et al. RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines. Oncogene, https://doi.org/10.1038/onc.2015.431 (2015).
Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinforma. 2015;31:166–9. https://doi.org/10.1093/bioinformatics/btu638.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.
Kortum RL, Sommers CL, Pinski JM, Alexander CP, Merrill RK, Li W, et al. Deconstructing Ras signaling in the thymus. Mol Cell Biol. 2012;32:2748–59. https://doi.org/10.1128/MCB.00317-12.
Priatel JJ, Teh SJ, Dower NA, Stone JC, Teh HS. RasGRP1 transduces low-grade TCR signals which are critical for T cell development, homeostasis, and differentiation. Immunity. 2002;17:617–27.
Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–34. https://doi.org/10.1038/nature12984.
Zhang CC, Lodish HF. Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol. 2008;15:307–11. https://doi.org/10.1097/MOH.0b013e3283007db5.
Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer. 2010;10:842–57. https://doi.org/10.1038/nrc2960.
Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019;291:134–53. https://doi.org/10.1111/imr.12796.
Mues M, Roose JP. Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. Small GTPases. 2017;8:20–25. https://doi.org/10.1080/21541248.2016.1187323.
Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, et al. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions. Blood. 2013;121:5203–7. https://doi.org/10.1182/blood-2012-12-475863.
Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70–71.
Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. ‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997;407:313–9.
Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho YJ, et al. Clonal dynamics of native haematopoiesis. Nature. 2014;514:322–7. https://doi.org/10.1038/nature13824.
Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 2013;504:143–7. https://doi.org/10.1038/nature12830.
Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, et al. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS ONE. 2018;13:e0193849. https://doi.org/10.1371/journal.pone.0193849.
Romero-Moya D, Bueno C, Montes R, Navarro-Montero O, Iborra FJ, Lopez LC, et al. Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function. Haematologica. 2013;98:1022–9. https://doi.org/10.3324/haematol.2012.079244.
Downward J. Cancer biology: signatures guide drug choice. Nature. 2006;439:274–5.
Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007;17:15–22. https://doi.org/10.1016/j.gde.2006.12.004.
Stine RR, Matunis EL. Stem cell competition: finding balance in the niche. Trends Cell Biol. 2013;23:357–64. https://doi.org/10.1016/j.tcb.2013.03.001.
Myers DR, Norlin E, Vercoulen Y, Roose JP. Active Tonic mTORC1 Signals Shape Baseline Translation in Naive T Cells. Cell Rep.2019;27:1858–74 e1856. https://doi.org/10.1016/j.celrep.2019.04.037.
Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2:640–53. https://doi.org/10.1002/wsbm.86.
Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93–106. https://doi.org/10.1038/nri1779.
Zhang Y, Gao S, Xia J, Liu F. Hematopoietic hierarchy - an updated roadmap. Trends Cell Biol. 2018;28:976–86. https://doi.org/10.1016/j.tcb.2018.06.001.
Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–3.
Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42.
Montes R, Ayllon V, Prieto C, Bursen A, Prelle C, Romero-Moya D. et al. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia. 2014;28:666–74. https://doi.org/10.1038/leu.2013.346.
Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126:2676–85. https://doi.org/10.1182/blood-2015-09-667378.
Sun C, Chang L, Zhu X. Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse. Oncotarget. 2017;8:35445–59. https://doi.org/10.18632/oncotarget.16367.
Beck-Engeser GB, Lum AM, Huppi K, Caplen NJ, Wang BB, Wabl M. Pvt1-encoded microRNAs in oncogenesis. Retrovirology. 2008;5:4.
Xu Z, Wang M, Wang L, Wang Y, Zhao X, Rao Q, et al. Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009;33:891–7. https://doi.org/10.1016/j.leukres.2009.01.041.
Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. cell stem cell. 2012;11:429–39. https://doi.org/10.1016/j.stem.2012.06.009.
Kentsis A, Look AT. Distinct and dynamic requirements for mTOR signaling in hematopoiesis and leukemogenesis. cell stem cell. 2012;11:281–2. https://doi.org/10.1016/j.stem.2012.08.007.
Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. cell stem cell. 2012;11:415–28. https://doi.org/10.1016/j.stem.2012.05.026.
Sanjuan-Pla A, Romero-Moya D, Prieto C, Bueno C, Bigas A, Menendez P. Intra-bone marrow transplantation confers superior multilineage engraftment of murine aorta-gonad mesonephros cells over intravenous transplantation. Stem Cells Dev. 2016;25:259–65. https://doi.org/10.1089/scd.2015.0309.
Pietras EM, Reynaud D, Kang YA, Carlin D, Calero-Nieto FJ, Leavitt AD, et al. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell. 2015;17:35–46. https://doi.org/10.1016/j.stem.2015.05.003.
Herault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, et al. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017;544:53–58. https://doi.org/10.1038/nature21693.
Roose JP, Diehn M, Tomlinson MG, Lin J, Alizadeh AA, Botstein D, et al. T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biol. 2003;1:E53.
This work was supported by an Alex’ Lemonade Stand Foundation Innovator Award, the NIH/NCI (R01 – CA187318), and the NIH/NHLBI (R01 – HL120724) (all to JPR). Further support came from a Leukemia & Lymphoma Society grant (to MM) and the Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering (to LK), and PD is a Mark Foundation Momentum Fellow supported by a fellowship from the Mark Foundation for Cancer Research; and by NCI grants CA021765 (St Jude Comprehensive Cancer Center Support Grant), an NCI R35 Outstanding Investigator Award (R35 CA197695) and a St. Baldrick’s Foundation Robert J. Arceci Innovation award. We thank the members of the Roose lab and the Heme-Onc community at UCSF for useful suggestions and comments. We thank UCSF flow cytometry facility and DRC Center Grant NIH P30 DK063720. We thank Emmanuelle Passague and her lab for kindly providing us Mx1-CRE mice.
Conflict of interest
Jeroen Roose is a co-founder and scientific advisor of Seal Biosciences, Inc. and on the scientific advisory committee for the Mark Foundation for Cancer Research. C.G.M. receives research funding from Loxo Oncology, Abbvie, and Pfizer, and speaking fees from Amgen.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Karra, L., Romero-Moya, D., Ksionda, O. et al. Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis. Oncogene 39, 6920–6934 (2020). https://doi.org/10.1038/s41388-020-01469-8